Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Use These 3 Simple Tricks to Maximize Your Returns From AbbVie Stock
06:22am, Friday, 23'rd Sep 2022
These strategies will work for other large biopharmas, too.
What Could This Drug News Mean for AbbVie?
06:16am, Friday, 23'rd Sep 2022
AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.
Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis
11:30am, Thursday, 22'nd Sep 2022
Could These Be Good Long Term Investments Into Cannabis? The post Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis appeared first on Marijuana Stocks | Cannabis Investments and News
3 Dividend Stocks You Can Safely Hold for Decades
10:00am, Thursday, 22'nd Sep 2022 The Motley Fool
These companies have solid track records -- and great prospects.
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
09:37am, Thursday, 22'nd Sep 2022 The Motley Fool
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
3 Dividend Stocks You Can Safely Hold for Decades
06:00am, Thursday, 22'nd Sep 2022
These companies have solid track records -- and great prospects.
Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
05:37am, Thursday, 22'nd Sep 2022
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
01:00pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
10:32am, Wednesday, 21'st Sep 2022
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication
04:10pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.
2 Dividend Stocks to Double Up On Right Now
02:45pm, Tuesday, 20'th Sep 2022 The Motley Fool
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication
01:33pm, Tuesday, 20'th Sep 2022
The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.
2 Dividend Stocks to Double Up On Right Now
10:45am, Tuesday, 20'th Sep 2022
These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.
The Zacks Analyst Blog Highlights Apple, Amazon, AbbVie, Philip Morris International and BlackRock
10:39am, Tuesday, 20'th Sep 2022 Zacks Investment Research
Apple, Amazon, AbbVie, Philip Morris International and BlackRock are included in this Analyst Blog.
AbbVie: Small Hurdle
11:05pm, Monday, 19'th Sep 2022
AbbVie has a small hurdle to overcome the impact of the LOE on key drug Humira. The company remains on path for a nearly $12 EPS stream at the low point in 2023 and 2024.
